Cargando…
Targeting E-selectin to Tackle Cancer Using Uproleselan
SIMPLE SUMMARY: This review focuses on eradicating cancer by targeting a surface protein expressed on the endothelium—E-selectin—with a novel drug, uproleselan (GMI-1271). Blocking E-selectin in the tumor microenvironment acts on multiple levels; uproleselan was shown (i) to inhibit cancer cell teth...
Autores principales: | Muz, Barbara, Abdelghafer, Anas, Markovic, Matea, Yavner, Jessica, Melam, Anupama, Salama, Noha Nabil, Azab, Abdel Kareem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831123/ https://www.ncbi.nlm.nih.gov/pubmed/33477563 http://dx.doi.org/10.3390/cancers13020335 |
Ejemplares similares
-
E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023) -
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019) -
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020) -
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015) -
Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)